ASCP News & Statements
Joint Statement on Federal Concerns About Psychotropic Medication Safety
March 26, 2025 The safety and efficacy of traditional antidepressants, antipsychotics, and mood stabilizers (such as lithium andsome anticonvulsants) and stimulant medications have been established through decades of rigorous research, randomized clinical trials,...
ASCP Statement on the Elimination of the Clozapine REMS
As of February 24, 2025, the FDA no longer expects prescribers, patients and pharmacists to participate in the risk evaluation and mitigation strategies (REMS) program for clozapine. This means pharmacies can dispense clozapine without knowledge of the patients...
Joint Statement on Federal Concerns About Psychotropic Medication Safety
The safety and efficacy of traditional antidepressants, antipsychotics, and mood stabilizers (such as lithium andsome anticonvulsants) and stimulant medications have been established through decades of rigorous research,randomized clinical trials, peer-reviewed...
Statement on Behalf of the ASCP Leadership on Federally Proposed Reduction of Indirect Cost Rates on Federal Grants
February 14, 2025 The American Society for Clinical Psychopharmacology (ASCP) has learned with significant concern about the National Institutes of Health (NIH) plan, shared on February 7 and scheduled to become effective on February 10, to limit the indirect cost...